Should You Buy Exelon Corp (EXC) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
44.410
1 Day change
-0.78%
52 Week Range
48.510
Analysis Updated At
2026/01/29
Exelon Corp (EXC) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown solid financial growth in its latest quarter, the stock faces regulatory and political challenges, slower earnings growth, and mixed analyst sentiment. The technical indicators and options data do not suggest a compelling entry point, and there are no strong proprietary trading signals. Holding the stock or waiting for a better entry point may be a more prudent strategy.
Technical Analysis
The MACD is positive but contracting, RSI is neutral at 49.937, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 44.416, with key resistance at 45.11 and support at 43.723. Overall, the technical indicators suggest a neutral trend.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Options data shows a low put-call ratio, indicating bullish sentiment, but the overall trading volume is low, and implied volatility is moderate at 21.29%.
Technical Summary
Sell
9
Buy
7
Positive Catalysts
Hedge funds are significantly increasing their positions in Exelon, with a 2344.75% rise in buying activity over the last quarter.
The company's Q3 2025 financials show strong revenue and net income growth, with revenue up 8.95% YoY and net income up 23.76% YoY.
Neutral/Negative Catalysts
Wolfe Research downgraded the stock, citing political and regulatory challenges and slower earnings growth.
Analysts have lowered price targets recently, with some firms expressing concerns over regulatory uncertainty and limited growth prospects.
Potential impact from Winter Storm Fern, which could disrupt operations and increase costs.
Financial Performance
Exelon reported strong financial performance in Q3 2025, with revenue increasing by 8.95% YoY to $6.7 billion, net income up 23.76% YoY to $875 million, and EPS up 22.86% YoY to 0.86. However, gross margin slightly declined by -0.58% YoY to 46.25%.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analyst sentiment is mixed. Wolfe Research downgraded the stock, citing regulatory challenges and slower growth. Barclays, Morgan Stanley, and Wells Fargo have slightly lowered price targets but maintain positive or neutral ratings. KeyBanc and UBS remain cautious, citing political pressures and limited near-term growth prospects.
Wall Street analysts forecast EXC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXC is 49.46 USD with a low forecast of 39 USD and a high forecast of 57 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast EXC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXC is 49.46 USD with a low forecast of 39 USD and a high forecast of 57 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
6 Hold
2 Sell
Moderate Buy
Current: 44.760
Low
39
Averages
49.46
High
57
Current: 44.760
Low
39
Averages
49.46
High
57
Wolfe Research
Outperform -> Peer Perform
downgrade
AI Analysis
2026-01-27
New
Reason
Wolfe Research
Price Target
AI Analysis
2026-01-27
New
downgrade
Outperform -> Peer Perform
Reason
Wolfe Research downgraded Exelon to Peer Perform from Outperform without a price target. The firm thinks political and regulatory "noise" in the company's key states and its below-average earnings growth of 5%-7% will hold back the stock's valuation. Wolfe expects expect an in-line 2026 guidance from Exelon.
Barclays
Nicholas Campanella
Overweight
downgrade
$52 -> $50
2026-01-22
Reason
Barclays
Nicholas Campanella
Price Target
$52 -> $50
2026-01-22
downgrade
Overweight
Reason
Barclays analyst Nicholas Campanella lowered the firm's price target on Exelon to $50 from $52 and keeps an Overweight rating on the shares. The firm adjusted targets in the power and utilities group as part of a Q4 preview.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EXC
